News

The two companies signed a license agreement in 2004 to research and develop disease-modifying therapeutic drugs for Alzheimer's disease and other memory-related disorders utilizing Acumen's amyloid-derived diffusible ligand

Earlier in the year, a GlaxoSmithKline sponsored a study discovered that its Relenza antiviral treatment is less likely to lead to drug-resistant flu strains than Tamiflu. Roche said

This is the second pivotal clinical study of Clolar in adult patients with acute myelogenous leukemia (AML) to commence this year, and Genzyme expects it to provide substantial

“MitoQ blocks the effects of oxidation, a chemical reaction that generates oxygen free radicals, which can attack and destroy cells. We achieved enrollment in this phase II trial

According to Sanofi Pasteur, the vaccines unit of Sanofi-Aventis, it has been able to produce more vaccine then it had originally projected in response to customer demand. The

The trials will examine the product’s safety according to a plan approved by the European Agency for Evaluation of Medicinal Products. Kamada has also signed a strategic agreement

The FDA asked for clarification and additional interpretation regarding certain data included in the application to assist in its evaluation. Oscient submitted its response to the approvable letter

The acquisition could potentially strengthen the company's oncology focus across Europe. Sales of Nipent in Europe last year were almost $5 million, with France, Germany, Greece, Italy and

Further data showed the compound's good safety profile and established the maximum tolerated dose, which will be the recommended dose for a phase II trial. In addition to